|
|
|
08.02.26 - 07:30
|
Canopy Growth-Aktie: Endlich Licht am Ende des Tunnels? (Sharedeals)
|
|
|
Die Canopy Growth-Aktie dümpelt seit Jahresbeginn knapp über der Marke von 1 US$ vor sich hin. Können die Quartalszahlen dem Cannabishersteller neuen Schwung verleihen uns sollten sich Anleger die Aktie ins Portfolio legen? Umsatz hui, Ergebnis pfui Es sich schon erstaunlich. In der Vergangenheit sorgte die Vorstellung der Quartalszahlen in der Regel für riesengroße Kurssprünge […]
The post Canopy Growth-Aktie: Endlich Licht am Ende des Tunnels? first appeared on sharedeals.de....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
06.02.26 - 15:12
|
Capital Rotation: Why Smart Money is Chasing Functional Wellness (PR Newswire)
|
|
|
ISSUED ON BEHALF OF DOSEOLOGY SCIENCES INC. Equity-Insider.com News Commentary VANCOUVER, BC, Feb. 6, 2026 /PRNewswire/ -- Legacy strategies are stalling as consumers abandon static products for brands that deliver real utility. This pivotal shift toward added value[1] is dismantling the......
|
|
|
|
|
|
|
06.02.26 - 14:39
|
Satellos Announces Pricing of US$50 Million Public Offering in Canada and the United States (Business Wire)
|
|
|
BASE SHELF PROSPECTUS IS ACCESSIBLE, AND PROSPECTUS SUPPLEMENT WILL BE ACCESSIBLE WITHIN TWO BUSINESS DAYS ON SEDAR+TORONTO--(BUSINESS WIRE)--Satellos Bioscience Inc. (TSX: MSCL, Nasdaq: MSLE) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announced the pricing of its previously announced public offering (the “Offering”) of 4,455,445 common shares and, in lieu of common shares for certain investors, pre-funded warrants to purchase 495,049 common shares. The common shares are being sold at a price of US$10.10 per share (C$13.81 per common share) and the pre-funded warrants are being sold at a price of US$10.09999 per pre-funded warrant (C$13.80999 per pre-funded warrant), which represents the per share price for the common share less the C$0.00001 per share exercise price for each pre-funded warrant. The pre-funded warrants do not expire. In addition, the Company has granted the underwriters ...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
06.02.26 - 13:06
|
Canopy Growth Reports Third Quarter Fiscal 2026 Financial Results (Business Wire)
|
|
|
Delivers double digit net revenue growth in Canada Cannabis contributing to a narrowing net loss; financial strength of $371M in cash and cash equivalents with a net cash position of $146M at December 31, 2025
Net loss in Q3 FY2026 narrowed by 49% year-over-year; Adjusted EBITDA1 loss narrowed by 17% year-over-year, resulting from strong sales execution and SG&A cost savings
Acquisition of MTL Cannabis remains on track to close in the current quarter. Transaction is expected to strengthen Canopy Growth's global cannabis platform
Strategic recapitalization completed in January 2026 further strengthened balance sheet, with maturity dates for all outstanding indebtedness in 2031SMITHS FALLS, Ontario--(BUSINESS WIRE)--Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX: WEED) (Nasdaq: CGC) today announced its financial results for the three months ended December 31, 2025 ("Q3 FY2026"). All financial information in this press release is reported in Canadian dollars,...
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
